Huadong Medicine (SHE:000963) subsidiary Zhongmei Huadong obtained the approval of China's drug regulator to conduct clinical trials of HDM2005 in combination with PD-1 and AD chemotherapy for classical Hodgkin's lymphoma.
The drug is already in trials for multiple hematologic and solid tumor indications in China and the U.S., according to a Thursday filing with the Shenzhen bourse.
Shares of the drugmaker declined 1% in recent trade.